Common Mechanisms of Anti-Suicidal Drug Action


About this study

The purpose of this study is to characterize the effects of clozapine, lithium, and ketamine on mTOR signaling, glucose uptake, and overall cellular metabolic function in peripheral blood mononuclear cells (PBMCs) from suicidal psychiatric inpatients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Suicidal ideation
  • Psychiatric inpatients
  • Ability to provide informed consent
  • Ages 16-55 years old
  • Will have a 9-item Patient Health Questionnaire (PHQ-9) suicide item (item 9) score of >1, and >2 on the Columbia Scale for Suicide Severity Rating (all at admission assessment)
  • Ability to pass comprehension assessment test related to this study
  • Voluntary admission

Exclusion Criteria:

  • Psychotic symptoms
  • Current alcohol or non-nicotine substance use disorder (unless in remission for >12 months)
  • Currently taking clozapine, lithium, or ketamine treatments
  • History of developmental delay or intellectual disorder
  • Pregnancy
  • Unstable medical condition
  • Involuntary psychiatric hospitalization

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kathryn Schak, M.D.

Closed for enrollment

Contact information:

Brooke Morath B.S.

(507) 255-4047

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer